Fig. 9.

Molecular markers of myocardial remodelling, fibrosis and Ca²⁺ handling in the left ventricle after doxorubicin (DOXO) treatment (cumulative dose 10 mg/kg BW; one injection per week for five consecutive weeks) measured two and five weeks after the last DOXO injection in Ren-2 transgenic hypertensive rats (TGR) in comparison to the control TGR (placebo-treated) groups. The gene expression was determined by qRT-PCR, the data were normalized on TBP (TATA-binding protein) as a reference gene and shown relative to the control group (control TGR 2 weeks). A Fibronectin 1(FN1); (B) Galectin 3 (LGALS3); (C): Collagen type I α1 chain (COL1A1); (D) Collagen type III α1 chain (COL3A1); (E): Ryanodine receptor 2 (Ryr2); (F) ATPase sarcoplasmic/endoplasmic reticulum Ca²⁺ transporting 2 (ATP2A2/SERCA2); P > 0.05 (NS); *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test